Y-Biologics, Inc
KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.
Price
Change
Market cap
Business overview
Source: DART corporate disclosureFounded in 2007 and listed on KOSDAQ in 2023, Y-Biologics is an antibody therapeutics developer. It holds the fully human antibody library Ymax®-ABL and a nanobody antibody library derived from it as its core antibody discovery platforms, and its business model centers on out-licensing and contract research organization (CRO) services. Its proprietary pipeline totals seven programs, four next-generation drug candidates and three immunomodulatory monoclonal antibodies, and its flagship candidate Multi-AbKine is a bispecific antibody-cytokine fusion combining the PD-1 inhibitor Acrixolimab (YBL-006), which has completed global Phase 1/2a trials, with an engineered interleukin-2 cytokine variant (IL-2v).
R&D and key agreements
Source: DART corporate disclosureYmax®-ABL · 플랫폼 기술 · Fully human antibody library platform, also applied to a nanobody antibody library
멀티앱카인(Multi-AbKine) · 암(면역항암) · Bispecific antibody-cytokine fusion built on PD-1 inhibitor Acrixolimab (YBL-006), which completed global Phase 1/2a trials, fused with an engineered IL-2 variant
독자개발 파이프라인(차세대 신약 4종, 면역조절 단일항체 3종) · Seven proprietary pipeline programs in total
AI reads
MAA server logs · IP-verifiedSomeone asked an AI a question, and it fetched this page live to answer.
Collected for later use. Not a signal of interest.
- OpenAIChatGPT-Useranswer3
- OpenAIOAI-SearchBot4
- PerplexityPerplexityBot1
Measured since Aug 25, 2026 · 2 AI engines · last read Aug 26, 2026
User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS.
Companies in the same categoryBiotech & Drug Discovery
KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.
Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.
Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.
EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.
A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.
KOSDAQ-listed biotech developing biomarker-driven targeted cancer therapies including lead candidate Vabametkib (ABN401).
KONEX-listed biotech venture developing new drug candidates with its multi-target fusion protein platform NTIG®
Biotech company developing fusion-protein immuno-oncology and allergy therapeutics, listed on KOSDAQ since 2023.
SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.
A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.
An ADC (antibody-drug conjugate) developer with its ConjuALL platform, having licensed pipeline assets to Janssen, Ono Pharmaceutical, and other global partners.
KOSDAQ-listed biopharma developing the BVAC cancer immunotherapy vaccine series and the AdCLD-CoV19-1 COVID-19 vaccine.
Sources and updates
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- AI visibility
- Measured 2026-08-13
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition